XBP1- IGFBP3 Signaling Pathway Promotes NSCLC Invasion and Metastasis

Author:

Luo Qingxi,Shi Wenwen,Dou Bo,Wang Jun,Peng Wei,Liu Xianyu,Zhao Deze,Tang Faqing,Wu Yingfang,Li Xizhe,Li Jiajia,Wen Siqi,Zhang Chunfang,Duan Chaojun

Abstract

Lung cancer is the most frequently diagnosed cancer and the main cause of cancer death in the world. X-box binding protein 1 (XBP1), which is an important transcription factor involved in regulating the unfolded protein response (UPR) during endoplasmic reticulum (ER) stress, might act as a potent oncogenic protein in the processes of tumorigenesis, tumor proliferation and metastasis in various cancers. However, the clinical significance and pathological role of XBP1 in non-small cell lung cancer (NSCLC) remains unknown. In this study, we investigated the expression of XBP1s protein in the 104 NSCLC tumor tissues and matched adjacent normal lung tissues (ANLT) by Immunohistochemical (IHC), and we found overexpressed XBP1s protein was associated with NSCLC TNM stages, lymph node metastasis and poor prognosis. The further gain-and loss-of-function experiments indicated overexpression of XBP1s protein promoted cell invasion, migration and metastasis both in vitro and in vivo. Further study showed XBP1s protein could upregulate insulin-like growth factor binding protein-3 (IGFBP3) expression, and regulated NSCLC cells invasion and metastasis by regulating IGFBP3. Taken together, XBP1s protein is markedly overexpressed in NSCLC and serves as an oncogene that play a critical role in NSCLC tumorigenesis and development. Importantly, XBP1s protein might not only be a potential biomarker for metastasis and prognosis but also a potential therapeutic target in NSCLC.

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference31 articles.

1. Cancer Statistics, 2020;Siegel;CA Cancer J Clin,2020

2. Exosome-Mediated Transfer of lncRna RP11838N2.4 Promotes Erlotinib Resistance in non-Small Cell Lung Cancer;Zhang;Int J Oncol,2018

3. Cancer Statistics, 2019;Siegel;CA Cancer J Clin,2019

4. Current WHO Guidelines and the Critical Role of Immunohistochemical Markers in the Subclassification of non-Small Cell Lung Carcinoma (NSCLC): Moving From Targeted Therapy to Immunotherapy;Osmani;Semin Cancer Biol,2018

5. Molecular Diagnostics and Targeted Therapies in non-Small Cell Lung Cancer (NSCLC): An Update;Jonna;Discov Med,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3